Advertisement
Singapore markets closed

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • Dow

    37,753.31
    -45.66 (-0.12%)
     

  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     

  • Bitcoin USD

    62,608.06
    -373.33 (-0.59%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,863.77
    +15.78 (+0.20%)
     

  • Gold

    2,397.00
    +8.60 (+0.36%)
     

  • Crude Oil

    82.32
    -0.37 (-0.45%)
     

  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     

  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    +35.97 (+0.50%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

Jim Halley, The Motley Fool
·5-min read
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.

Continue reading